Thwarting AAV-Neutralizing Antibodies Could Improve Gene Therapy
Adeno-associated viral vectors can deliver gene therapies, but AAV-neutralizing antibodies might prevent the medicines from working. (Source: The Scientist)
Source: The Scientist - September 25, 2020 Category: Science Tags: News & Opinion Source Type: news

Reuters Events' Cell & Gene Therapy USA
2 November 2020, Virtual Event, USA. Join 2500+ gene and cell therapy leaders for this (free to attend) conference brough to you by Reuters Events. The race to commercialize cell & gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market. (Source: World Pharma News)
Source: World Pharma News - September 24, 2020 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Gene Therapy Clinical Trial for Mesothelioma Moving Forward
This study will compare the effectiveness of the drug against a control group receiving only the gemcitabine and celecoxib. Patients have a one-in-two chance of being randomly assigned to either the adenovirus treatment or the control group. Adenovirus-delivered interferon Alpha-2b is designed as a second- or third-line treatment for patients who have failed in earlier regimens. Patients who previously had aggressive mesothelioma surgery but whose tumors have since progressed would be eligible to enroll. Success at the phase III level would mark the culmination of 20 years of researching and fine tuning gene therapy for us...
Source: Asbestos and Mesothelioma News - September 23, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Advantages of Oncolytic Viruses as Immunotherapies to be Discussed by...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb September 22, 2020)Read the full story at https://www.prweb.com/releases/advantages_of_oncolytic_viruses_as_immunotherapies_to_be_discussed_by_catalent_gene_therapy_expert_at_world_vaccine_congress/prweb17410197.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 22, 2020 Category: Pharmaceuticals Source Type: news

NC firm extends cancer-focused collaboration with a global pharma
A Triangle gene therapy company is adding more cancer targets to its sights through a partnership with a global pharmaceutical company based in France. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 21, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

Durham firm extends cancer-focused collaboration with a global pharma
A Triangle gene therapy company is adding more cancer targets to its sights through a partnership with a global pharmaceutical company based in France. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 18, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

Durham firm extends cancer-focused collaboration with a global pharma
A Triangle gene therapy company is adding more cancer targets to its sights through a partnership with a global pharmaceutical company based in France. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Seth Thomas Gulledge Source Type: news

Gene therapy corrects the cardiac effects of Friedreich's ataxia
(Mary Ann Liebert, Inc./Genetic Engineering News) Gene therapy was successfully used to overcome the cardiac effects of Freidreich's ataxia (FA) in a mouse model of the disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2020 Category: International Medicine & Public Health Source Type: news

How this Stanford biotech spinout plans to quickly boost gene therapy
The Peninsula startup snared a $45 million Series A round but plans to start a clinical trial in sickle cell disease as early as the first half of next year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 16, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

How this Stanford biotech spinout plans to quickly boost gene therapy
The Peninsula startup snared a $45 million Series A round but plans to start a clinical trial in sickle cell disease as early as the first half of next year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

From complexity to clarity in cell and gene therapy
One of the most exciting frontiers in medicine, cell and gene therapies are already offering breakthrough treatments and potential cures in severe genetic diseases and cancer. The innovations continue to advance rapidly, with press releases announcing major breakthroughs on a seemingly monthly basis.  It ’s undoubtedly a good news story but these advances bring with them the challenge of explaining all the exciting, but complex possibilities to patients and caregivers.  The groups that have historically been expected to help keep doctors up to speed cannot be expected to do so in this dynamic environm...
Source: EyeForPharma - September 16, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Catalent Biologics and Humanigen to Present a Case Study on...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb September 16, 2020)Read the full story at https://www.prweb.com/releases/catalent_biologics_and_humanigen_to_present_a_case_study_on_accelerated_scale_up_of_a_monoclonal_antibody_to_treat_covid_19_at_bioprocess_international_conference/prweb17400043.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 16, 2020 Category: Pharmaceuticals Source Type: news

Researchers gain head start in coronavirus vaccine race
Fast-track techniques used in cell and gene therapies are proving invaluable in the fight against Covid-19 (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 15, 2020 Category: Pharmaceuticals Source Type: news

Readers Predict Biggest Medical Breakthroughs by 2045 Readers Predict Biggest Medical Breakthroughs by 2045
As part of Medscape's 25th anniversary, readers were asked what they predict will change medicine in the next 25 years. Gene therapy advances and cancer cures topped the list.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 11, 2020 Category: Transplant Surgery Tags: Family Medicine/Primary Care News Source Type: news

The Petri Dish: An IPO revisited and Sarepta's gene therapy
Takeda made further moves to pay off its $40 billion in debt. Meanwhile, startup Casma Therapeutics raised a Series B round. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 10, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Obsidian Therapeutics Appoints Rob Ross, M.D., to Board of Directors
Board expansion supports ongoing development of cytoDRiVE™ programs and external collaborations CAMBRIDGE, Mass., Sept. 3, 2020 -- (Healthcare Sales & Marketing Network) -- Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable ce... Biopharmaceuticals, Personnel Obsidian Therapeutics, gene therapies, cytoDRiVE (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 3, 2020 Category: Pharmaceuticals Source Type: news

Philadelphia gene therapy pioneer Spark Therapeutics in full-tilt growth mode despite pandemic
The company has hired 130 people this year and plans to continue the hiring spree into 2021. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 3, 2020 Category: Biotechnology Authors: John George Source Type: news

Dallas ’ Taysha Gene Therapies – after loading up on more than $100M in funding – files for an IPO
Another North Texas company is looking for a move to the public markets. Dallas’ Taysha Gene Therapies filed for an initial public offering on Wednesday with the U.S. Securities and Exchange Commission. The filing follows a haul in July and August of $107.1 million in net proceeds from an additional closing of a Series A convertible preferred stock financing and a Series B convertible preferred stock, according to the document. Since its founding it’s raised more than $125 million. Taysha… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 3, 2020 Category: Biotechnology Authors: Brian Womack Source Type: news

Dallas ’ Taysha Gene Therapies – after loading up on more than $100M in funding – files for an IPO
Another North Texas company is looking for a move to the public markets. Dallas’ Taysha Gene Therapies filed for an initial public offering on Wednesday with the U.S. Securities and Exchange Commission. The filing follows a haul in July and August of $107.1 million in net proceeds from an additional closing of a Series A convertible preferred stock financing and a Series B convertible preferred stock, according to the document. Since its founding it’s raised more than $125 million. Taysha… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 3, 2020 Category: Pharmaceuticals Authors: Brian Womack Source Type: news

Gene therapy research for HIV awarded $14.6 million NIH grant
(Keck School of Medicine of USC) An HIV research program led by scientists at USC and the Fred Hutchinson Cancer Research Center has received a five-year, $14.6 million grant from the National Institutes of Health. The team is advancing a gene therapy approach to control the virus without the need for daily medicines. The NIH award will support preclinical studies that combine gene editing against HIV with technologies for safer and more effective hematopoietic stem cell transplants. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 2, 2020 Category: Infectious Diseases Source Type: news

Toxicity of dorsal root ganglia is widely associated with CNS AAV gene therapy
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of non-human primate (NHP) studies showed that adeno-associated virus (AAV) gene therapy often caused dorsal root ganglion (DRG) pathology. There were no clinical effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 2, 2020 Category: International Medicine & Public Health Source Type: news

Scientists Use Gene Therapy to Tackle Oral Herpes in Mice
MONDAY, Aug. 31, 2020 -- Gene therapy has nearly eliminated the oral herpes virus in lab animals, researchers report. Using a gene editing technique, they achieved at least a 90% reduction in latent herpes simplex virus 1 (HSV-1) in mice, which... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 31, 2020 Category: General Medicine Source Type: news

The Scientist Speaks Podcast - Episode 8
Experimental Cures for Fragile Patients: Prenatal Stem Cell and Gene Therapies (Source: The Scientist)
Source: The Scientist - August 26, 2020 Category: Science Tags: Sponsored Videos Source Type: news

Power tool for genome engineering snags $100M round, signaling potential IPO
The Peninsula company's latest funding round is designed to help it deliver top-quality genome-editing tools to researchers and companies for cell therapies and gene therapies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 26, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Progress toward a treatment for Krabbe disease
(University of Pennsylvania) The inherited disease, which typically kills children before their second birthday, has no cure, but a University of Pennsylvania study in a canine model offers hope for an effective gene therapy with lasting results. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 26, 2020 Category: International Medicine & Public Health Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

A multicenter look at gene therapy for spinal muscular atrophy
(Nationwide Children's Hospital) A new study confirms the safety and efficacy of gene therapy in children with spinal muscular atrophy under two years old. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 25, 2020 Category: Biology Source Type: news

Technologies to Enhance Cell Line Productivity and Expand...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb August 25, 2020)Read the full story at https://www.prweb.com/releases/technologies_to_enhance_cell_line_productivity_and_expand_antibody_drug_conjugate_therapeutic_window_to_be_presented_by_catalent_biologics_at_pegs/prweb17346332.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 25, 2020 Category: Pharmaceuticals Source Type: news

After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
A controversial drug to treat the most common form of dwarfism is heading for a federal regulator's decision. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) of San Rafael said Thursday that it submitted its new drug application for the Food and Drug Administration to approve its drug, called vosoritide, as a once-daily injection for children with achondroplasia. The bone-growth disorder prevents cartilage fr om changing into bone. The application comes a day after the FDA rejected BioMarin's request… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
A controversial drug to treat the most common form of dwarfism is heading for a federal regulator's decision. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) of San Rafael said Thursday that it submitted its new drug application for the Food and Drug Administration to approve its drug, called vosoritide, as a once-daily injection for children with achondroplasia. The bone-growth disorder prevents cartilage fr om changing into bone. The application comes a day after the FDA rejected BioMarin's request… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 20, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA blocks much-anticipated BioMarin hemophilia gene therapy
BioMarin Pharmaceutical shares plunged by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients (Source: ABC News: Health)
Source: ABC News: Health - August 19, 2020 Category: Consumer Health News Tags: Health Source Type: news

Promising gene therapy against hemophilia rejected by FDA
BioMarin had gone so far as to give its hemophilia A gene therapy a name. Now it will have to deliver more data to the FDA. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 19, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Could Gene Therapy Stem the Damage of Parkinson's?
WEDNESDAY, Aug. 19, 2020 -- It may be possible to protect Parkinson's patients'brains from further damage by turning off a " master regulator " gene, researchers report. " One of the biggest challenges in treating Parkinson's, other than the lack of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 19, 2020 Category: General Medicine Source Type: news

New gene therapy approach eliminates at least 90% latent herpes simplex virus 1
(Fred Hutchinson Cancer Research Center) Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes. In animal models, the findings show at least a 90 percent decrease in the latent virus, enough researchers expect that it will keep the infection from coming back. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 18, 2020 Category: Infectious Diseases Source Type: news

The Petri Dish: FDA lifts gene therapy hold and PPP recipient raises $100M
A life sciences company that returned its PPP loan raised nearly $100 million in a stock sale and a muscle disease startup raised $115 million. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 13, 2020 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2020 -- (Healthcare Sales & Marketing Network) -- StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith ... Biopharmaceuticals, Personnel StrideBio , gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 11, 2020 Category: Pharmaceuticals Source Type: news

Gene Therapy Promising in BCG-Unresponsive Bladder Cancer Gene Therapy Promising in BCG-Unresponsive Bladder Cancer
An investigative intravesical viral gene therapy may offer a bladder-sparing alternative for some patients with high-grade, nonmuscle invasive bladder cancer who have few options, results from a phase 3 study show.Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - August 6, 2020 Category: Urology & Nephrology Tags: Urology News Source Type: news

Catalent Gene Therapy Facility Receives FDA Approval as an Additional...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb August 06, 2020)Read the full story at https://www.prweb.com/releases/catalent_gene_therapy_facility_receives_fda_approval_as_an_additional_manufacturing_site_for_avexis_gene_therapy/prweb17307018.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 6, 2020 Category: Pharmaceuticals Source Type: news

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires,...
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing, solutions for drugs, biologics, cell and gene therapies, and consumer health products, today...(PRWeb August 04, 2020)Read the full story at https://www.prweb.com/releases/catalent_adds_potent_manufacturing_capabilities_at_its_buenos_aires_argentina_site/prweb17300982.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 4, 2020 Category: Pharmaceuticals Source Type: news

Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
A searchable database with information about all FDA-licensed biological products regulated by CDER, including licensed biosimilar and interchangeable products, and their reference products, and FDA-licensed allergenic, cellular and gene therapy, hematologic, and vaccine products regulated by CBER. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Sangamo and Novartis join forces to create gene therapies for autism and other brain disorders
Bay Area biotechnology company Sangamo Therapeutics has teamed up with multinational  pharmaceutical giant Novartis International AG to take on autism spectrum disorder and other neurodevelopmental conditions. The collaboration, announced Thursday, will net Sangamo an upfront fee of $75 million with the potential to rake in $720 million, contingent on the Brisbane-base company’s ability to meet developmental and commercial milestones. It will also get a percentage— single-digit to sub-teens-digits—… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 30, 2020 Category: Biotechnology Authors: Brian Rinker Source Type: news

Sangamo and Novartis join forces to create gene therapies for autism and other brain disorders
Bay Area biotechnology company Sangamo Therapeutics has teamed up with multinational  pharmaceutical giant Novartis International AG to take on autism spectrum disorder and other neurodevelopmental conditions. The collaboration, announced Thursday, will net Sangamo an upfront fee of $75 million with the potential to rake in $720 million, contingent on the Brisbane-base company’s ability to meet developmental and commercial milestones. It will also get a percentage— single-digit to sub-teens-digits—… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 30, 2020 Category: Pharmaceuticals Authors: Brian Rinker Source Type: news

Durham biotech uses new funding to acquire gene therapy for eye disease
A Hatteras backed early stage life science company has used its new funding to acquire the exclusive rights to a gene therapy platform targeting eye disease. On Wednesday, Durham-based Atsena Therapeutics announced that it has acquired the exclusive rights to a gene therapy from French pharma giant Sanofi. The therapy targets GUCY2D-associated Leber congenital amaurosis (LCA1) – a genetic eye disease that affects the retina and is a leading cause of blindness in children. The acquisition follows… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 29, 2020 Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news

New CMS Proposed Rule Encourages Value-Based Reimbursement Based on Patient Outcomes When Payers and Drug Manufacturers Negotiate Payment for Pricey Therapies
Clinical laboratories and anatomic pathology groups should consider this another example of how CMS is taking forward steps to encourage value-based payment arrangements throughout the health system With the sky-high cost of many prescription drugs and gene therapies, it was only a matter of time before the Centers for Medicare and Medicaid Services (CMS) would […] (Source: Dark Daily)
Source: Dark Daily - July 29, 2020 Category: Laboratory Medicine Authors: Jude Tags: Compliance, Legal, and Malpractice Laboratory Management and Operations Laboratory News Laboratory Operations Laboratory Pathology Laboratory Testing Alexander Dworkowitz anatomic pathology centers for medicare and medicaid services clin Source Type: news

A new cell & gene therapy approach to treat common bleeding disorder
(Wake Forest Baptist Medical Center) WFIRM researchers have developed an optimized cellular platform for delivering Factor 8 to better treat patients with hemophilia A. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2020 Category: International Medicine & Public Health Source Type: news

A Boy With Muscular Dystrophy Was Headed For A Wheelchair. Then Gene Therapy Arrived
(Source: NPR Health and Science)
Source: NPR Health and Science - July 27, 2020 Category: Consumer Health News Authors: Jon Hamilton Source Type: news

Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Dear Investor, Please find attached a press release by Sarepta Therapeutics:https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-receives-fast-track-designation-srp-9001 Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - July 24, 2020 Category: Pharmaceuticals Source Type: news

Phase III data show Roche ’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration
Basel, 22 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from the phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of blindness globally.1 In Archway, 98.4% of PDS patients were able to go six months without needing additional treatment and achieved vision outcomes equivalent to patients receiving monthly ranibizumab eye injections, a current standard of care. In the study, PDS was generally well-tolerated, with a favourable benefit...
Source: Roche Media News - July 22, 2020 Category: Pharmaceuticals Source Type: news